Literature DB >> 9642672

Dual response of calpain to rat brain postdecapitative ischemia.

T Zalewska1, B Zabłocka, T C Saido, H Zajac, K Domańska-Janik.   

Abstract

Calpains, Ca(2+)-dependent neutral proteinases (microM and mM Ca(2+)-sensitive), and their endogenous inhibitor calpastatin were examined in rat brain. Specific activity of m-calpain exceeded almost 10 times that of mu-calpain, and the both isoforms of calpain together with calpastatin were mainly located in the soluble fraction of homogenate. Acute postdecapitative ischemia of 15 min duration resulted in a gradual, time-dependent decrease of total mu-calpain activity (to 60% of control values) and in the moderate elevation of calpastatin activity (by 28%). The decrease of total mu-calpain activity coincided with its remarkable increase (above 300% of control values) in particulate fraction. In the case of m-calpain, the only observed effect of ischemia was its redistribution and, as a consequence, the elevation of activity in particulate fraction. The accumulation of breakdown products, resulting from calpain-catalyzed proteolysis of fodrin (as revealed by Western blotting) indicated activation of calpain under ischemia. The findings suggest that this rapid activation involves partial enzyme translocation toward membranes, and is followed (at least in acute phase) by mu-calpain downregulation and increased calpastatin activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9642672     DOI: 10.1007/bf02815181

Source DB:  PubMed          Journal:  Mol Chem Neuropathol        ISSN: 1044-7393


  2 in total

Review 1.  The role of calcium-activated protease calpain in experimental retinal pathology.

Authors:  M Azuma; T R Shearer
Journal:  Surv Ophthalmol       Date:  2008 Mar-Apr       Impact factor: 6.048

2.  In vitro proteolytic degradation of bovine brain calcineurin by m-calpain.

Authors:  Ashakumary Lakshmikuttyamma; Ponniah Selvakumar; Anil Ratan Sharma; Deborah H Anderson; Rajendra K Sharma
Journal:  Neurochem Res       Date:  2004-10       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.